AI Article Synopsis
- * This study explores the identification of specific metabolic biomarkers that can predict how well patients will respond to neoadjuvant therapy, based on a review of 108 articles from the past decade.
- * Research indicates that metabolomic analysis of CRC samples is linked to worse progression-free survival rates, highlighting the importance of biomarkers in tailoring targeted therapies and understanding drug resistance.
Article Abstract
Colorectal cancer (CRC) is one of the most aggressive, heterogenous, and fatal types of human cancer for which screening, and more effective therapeutic drugs are urgently needed. Early-stage detection and treatment greatly improve the 5-year survival rate. In the era of targeted therapies for all types of cancer, a complete metabolomic profile is mandatory before neoadjuvant therapy to assign the correct drugs and check the response to the treatment given. The aim of this study is to discover specific metabolic biomarkers or a sequence of metabolomic indicators that possess precise diagnostic capabilities in predicting the efficacy of neoadjuvant therapy. After searching the keywords, a total of 108 articles were identified during a timeframe of 10 years (2013-2023). Within this set, one article was excluded due to the use of non-English language. Six scientific papers were qualified for this investigation after eliminating all duplicates, publications not referring to the subject matter, open access restriction papers, and those not applicable to humans. Biomolecular analysis found a correlation between metabolomic analysis of colorectal cancer samples and poor progression-free survival rates. Biomarkers are instrumental in predicting a patient's response to specific treatments, guiding the selection of targeted therapies, and indicating resistance to certain drugs.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10889270 | PMC |
| http://dx.doi.org/10.3390/ijms25042381 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Second-line systemic treatment for metastatic colorectal cancer: A systematic review and Bayesian network meta-analysis based on RCT.
PLoS One
December 2024
Department of Colorectal Surgery, The Affiliated Xuzhou Clinical College of Xuzhou Medical University, Xuzhou Central Hospital, Xuzhou, Jiangsu, China.
Background: The optimal second-line systemic treatment for metastatic colorectal cancer (mCRC) is inconclusive.
Methods: We searched PubMed, Web of Science, EMBASE, and Cochrane Library for RCTs comparing second-line systemic treatments for mCRC from the inception of each database up to February 3, 2024. Markov Chain Monte Carlo (MCMC) technique was used in this network meta-analysis (NMA) to generate the direct and indirect comparison results among multiple treatments in progression-free survival (PFS), overall response rate (ORR), overall survival (OS), complete response (CR), partial response (PR), grade 3 and above adverse events (Grade ≥ 3AE), and any adverse events (Any AE).
Objective: Aim: To evaluate and compare the functional outcomes and quality of life in distal rectal cancer patients after low anterior resection with the formation of a transverse double-fold reservoir (TDFR) and without it.
Patients And Methods: Materials and Methods: The retrospective study enrolled 80 patients with distal rectal cancer: 40 patients who underwent low anterior resection with the formation of a TDFR, and 40 patients with the formation of a colorectal anastomosis (control group). The follow-up period was 10-60 months, with a median follow-up of 36 months after primary surgery.
Level of Information and Awareness About Colorectal Cancer and Its Screening Program in Türkiye: A Community-Based Cross-Sectional Study.
Public Health Nurs
December 2024
Nursing Department, Division of Gynecology and Obstetrics Nursing, Faculty of Health Sciences, Bartın University, Bartın, Turkey.
Objective: Colorectal cancer (CRC) has high mortality if it is detected in advanced stages, persons can lower their risk of CRC by adopting a healthy lifestyle that may lead to prevention. Screening is the most powerful public health tool to reduce mortality, considering the challenges of making substantial lifestyle changes or implementing widespread primary prevention strategies to lower the risk of CRC. This study aims to find out the levels of information and awareness about CRC and its screening program in individuals living in Türkiye.
View Article and Find Full Text PDFReduced-port laparoscopic right colonic resection with D3 lymph node dissection and transvaginal specimen extraction (NOSES VIIIa) for right colon cancer: clinical features.
Tech Coloproctol
December 2024
Department of Faculty Surgery No. 2, I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia.
Background: Reduced-port laparoscopic surgery (RPLS) uses the minimum possible number of ports or small-sized ports in laparoscopic surgery. The combination of RPLS and natural orifice specimen extraction (NOSE) minimizes the procedural damage.
Methods: A total of 17 patients diagnosed with right colon cancer were included: 5 patients in the RPLS + NOSE group and 12 patients in the conventional laparoscopic surgery (CL) + mini-laparotomy (ML) group.
HER-2 SMASH.
Cancer Chemother Pharmacol
December 2024
Departments of Pharmacology, Medicine Faculty, Sivas Cumhuriyet University, Sivas, Türkiye.
Purpose: Human epidermal growth factor-2 (HER-2) targeted drugs are used in only HER-2 overexpressed cancers. However, only a small portion of these cancer types are HER-2 overexpressed. In this study, we aimed to upregulate HER-2 receptors in MCF-7 breast cancer and HT-29 colon cancer cell cultures, which these cells are not HER-2 upregulated in natural status.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!